UK accepts all 44 AI-in-healthcare recommendations, ending one-off device approvals
The government confirmed on October 6 it will accept all 44 recommendations from the NHS-doctors-led National Commission into the Regulation of AI in Healthcare. AI-enabled medical devices will now be assessed and monitored throughout their working life, not just at approval — and the MHRA has opened applications for Phase 3 of its AI Airlock regulatory sandbox to put that lifecycle approach into practice.
The government has today, 6 October 2026, confirmed it will accept all 44 recommendations made by the National Commission into the Regulation of AI in Healthcare — the NHS-doctors-led panel that published its report on September 10 after a year-long evidence programme involving more than 12,000 patients, clinicians and members of the public. Ministers have also set out how the recommendations will be delivered across the UK.
The centrepiece is a shift in how AI-enabled medical devices are regulated: from a single pre-approval safety check to a proportionate, lifecycle-based framework. One of the Commission's central conclusions was that AI devices should be assessed and monitored throughout their working life to better understand their true performance, instead of over-relying on one-time assessments — a direct answer to the reality that modern models keep learning and adapting after deployment.
Non-deterministic algorithms, continuous oversight
"We're moving into a much more sophisticated and complex era of AI as a medical device where we have non-deterministic algorithms," MHRA chief executive Lawrence Tallon told Reuters — referring to AI systems that evolve and adapt while doctors are using them. Reuters reports Britain is the first country to develop comprehensive rules for the technology, and that other nations are already approaching the UK to learn from its approach.
AI Airlock Phase 3 opens today
Alongside the response, the MHRA opened applications for the third phase of AI Airlock, its regulatory sandbox for AI-enabled medical devices, with testing themes directly informed by the Commission's recommendations. Phase 3 focuses specifically on post-market surveillance and lifecycle regulation — working with real products and technologies, it brings together innovators, regulators and healthcare partners to explore how AI devices can be monitored and managed safely once deployed, generating evidence that will directly inform future MHRA guidance.
The programme secured three years of additional government funding. Applications are open now, a webinar for prospective applicants takes place on 22 October, and the first wave of innovators will be selected in November 2026.
What comes next
The MHRA is committed to issuing draft guidance by December 2026 on a new approach to managing changes to AI-enabled medical devices as they adapt and improve over time, and will begin next year by consulting on how to qualify and classify AI-enabled devices — the Commission's first recommendation. The government is also exploring staged authorisation pathways that would let promising AI tools be used in the NHS earlier under close supervision while further real-world evidence is gathered.
A newly established Programme Board convenes with work already under way across government, the MHRA, NHS partners and the devolved authorities on the ten priority areas set out in the response. A full implementation roadmap, setting out timelines and responsibilities across all 44 recommendations, will be published by spring 2027, with regular progress updates to follow.
Why it matters
Most AI regulation to date treats approval as the finish line. The UK's bet is that for adaptive, non-deterministic systems, the finish line is an illusion — and that the country that figures out safe continuous monitoring gets faster patient access and a regulatory export. The parallel commitments also answer the trust question directly: patients must be informed about when AI is used in their care, patient engagement in decision-making must strengthen, and access to redress where standards of care fall short must improve. As MHRA's Tallon put it, the goal is to make the UK "the best place to get AI products to patients safely, quickly and in a way that maintains public trust."